The acquisition establishes Nemera’s operations footprint in Eastern Europe.
Nemera has entered into an agreement to acquire Copernicus, based in Szczecin Poland. Founded in 2004, the company specialises in the development and manufacturing of injection devices. Its range of reusable and disposable pen injectors are tailored for the treatment of several chronic pathologies.
The acquisition will increase Nemera’s small series production capabilities, R&D capabilities and parenteral product offering. It will also expand its overall proprietary product portfolio.
Copernicus’s clinical manufacturing, adapted for small series, complements Nemera’s large scale manufacturing capabilities. Furthermore, Copernicus’ marketed reusable pen injectors are beneficial to Nemera’s sustainability goals, the company says.
The companies will work together to build a manufacturing facility in Szczecin, Poland.
Marc Hämel, CEO of Nemera said: “This acquisition is a great strategic and cultural fit for us. Copernicus’ strong focus on patient needs aligns perfectly with our purpose of always putting the patient at the center of everything we do. We’re about to write a new chapter of Nemera’s growth story and I’m really excited about our bright future”.
“Nemera’s unaltered focus on patient needs and passion to develop combination product solutions of the future convinced us that this was the right next step. We’re thrilled to join Nemera and together make products that truly improve patients’ lives” added Alberto Lozano, CEO of Copernicus.